NIH Panel - Commercializing SBIR/STTR Technologies

Featuring Co-Founder and Executive Chairman Dr. Evan Unger As Panelist in Commercializing SBIR/STTR Technologies Discussion at 2025 BIO International Convention

Tucson, AZ – June 18, 2025 – NuvOx Therapeutics, Inc. (“NuvOx”) is pleased to announce Executive Chairman and Co-Founder, Dr. Evan Unger, as speaker on the NIH Panel Commercializing SBIR/STTR Technologies at the 2025 BIO International Convention on June 18th in Boston, MA, Room 210A, 2:30 pm EST, Boston Convention Center (Commercializing SBIR/STTR Technologies - BIO International Convention 2025).  

As a founder of 4 biotech companies and inventor on 127 issued patents, Dr. Unger will discuss his experience with the application of non-dilutive funding as a catalyst to innovation in the biopharmaceutical and life sciences industry.  In his previous companies, non-dilutive funding has helped Dr. Unger to develop 3 FDA approved drugs.

Dr. Unger and NuvOx have received multiple NIH SBIR grants, including Phase I, Phase II, Phase IIb grants as well as contract awards from the DOD and BARDA. In addition, collaborating partners received multiple non-dilutive funding contract in applying NuvOx’s product – NanO2TM, in clinical and pre-clinical researches.  In its three active clinical programs, NuvOx has been able to leverage such non-dilutive funding in preparing and conducting ongoing trials.   Such non-dilutive funding has enabled great capital efficiency for NuvOx, the rigorous review and award of non-dilutive funding also serve as technical validation for NuvOx’s oxygen therapeutics platform.

About NuvOx:

NuvOx is a privately held clinical-stage biopharmaceutical company developing a novel platform of oxygen therapeutics for the treatment of diseases where hypoxia plays a role. Hypoxia, or low oxygen, is responsible for resistance to cancer treatment, brain damage in stroke, and the death of patients with acute respiratory distress syndrome (ARDS).

The Company’s drug candidate- NanO2 represents a potentially disruptive platform technology addressing multiple unmet needs, with positive results demonstrated in two completed Phase Ib/II studies: one in glioblastoma as a radiosensitizer and the other in stroke as a neuroprotectant. It was shown to be the most promising oxygen therapeutic among 74 clinical-stage compounds in a literature review. It has safety and efficacy data in 7+ indications in various preclinical and clinical stages, including Orphan Drug Designation for both glioblastoma and sickle cell anemia.

The product can refer to safety data in ~2,000 subjects. The product is designed to be synergistic, rather than competitive with standard of care. The company also has a strong IP portfolio: 11 patent families, 11 issued US patents and 31 foreign equivalents.

NuvOx is conducting a Phase IIb clinical trial as a radiosensitizer in treatment of glioblastoma, a Phase Ib clinical trial in treatment of respiratory distress, and also plans to start a Phase IIb clinical trial in the treatment of ischemic stroke

Investor Relations

Hanover International, Inc.

E: ka@hanoverintlinc.com

Forward-looking statement

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws.  Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "antici-pates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.